The discontinuation of the PDS0101 Phase 3 trial is a significant negative catalyst, effectively writing off the company's most advanced asset. The entire valuation now rests on PDS0301 Phase 2b data expected over the next 18-24 months, creating a binary, high-risk profile. Traders should monitor for any partnership announcements for PDS0101 and the upcoming Q2 earnings on August 13 for cash runway details.
Price Chart
Executive Summary
PDS Biotechnology announced a strategic refocus prioritizing PDS0301 in metastatic colorectal cancer (mCRC) and discontinuing internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, seeking a partnership for PDS0101 instead. The company cited encouraging Phase 2 data for PDS0301, including a 71% ORR at 6 months and 80% 24-month survival in MSS/pMMR mCRC with liver metastases. This is a material pipeline restructuring that abandons the most advanced program (PDS0101 Phase 3) in favor of an earlier-stage asset, creating significant binary risk around PDS0301's upcoming Phase 2b data.
Key Facts
- PDS Biotech is discontinuing the PDS0101 Phase 3 VERSATILE-003 trial and ceasing further internal investment in PDS0101.
- The company is prioritizing PDS0301, an earlier-stage tumor-targeted immunocytokine, as its lead development program.
- PDS0301 Phase 2 data in MSS/pMMR mCRC with liver metastases showed a 71% ORR at 6 months and an 80% 24-month survival rate.
- PDS0301 has been evaluated in over 380 patients with an encouraging safety profile.
- A randomized Phase 2b trial for PDS0301 has been designed with FDA feedback, with advancement expected over the next 18-24 months.
- The company will announce Q2 2026 financial results on August 13, 2026.
- Market cap is $41M, with 89% analyst bullish consensus but a 33% historical win rate on prior calls.
Financial Impact
No financial figures provided in the filing. The company is a clinical-stage biotech with no approved products or reported revenue. The strategic refocus involves discontinuing the most advanced pipeline program (PDS0101 Phase 3), which represents a significant write-off of prior development investment.
Risk Factors
- PDS0301 Phase 2b trial may fail to replicate earlier efficacy signals, resulting in a complete loss of enterprise value.
- No partnership for PDS0101 may materialize, leaving zero value from that program.
- Cash runway may be insufficient to complete the PDS0301 Phase 2b trial without dilutive financing.
- The 33% historical win rate on prior PDSB calls suggests the stock has been difficult to predict directionally.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-032142 |
| Document: ef20079931_8k.htm | 0001140361-26-032142 |
| Document: 0001140361-26-032142-index-headers.html | 0001140361-26-032142 |
| Document: 0001140361-26-032142-index.html | 0001140361-26-032142 |
| Document: 0001140361-26-032142.txt | 0001140361-26-032142 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7366 (−145.53%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7366 (+252.61%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7366 (−215.87%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7366 (−186.61%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7366 (−2.95%) |
Jun 26, 2026 13w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7366 (−18.07%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7366 (+23.27%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7366 (−27.78%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7366 (−36.50%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7366 (−44.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access